Biocartis

Biocartis is a Belgium-based diagnostics company that provides testing solutions for the treatment of cancer and infectious diseases with a focus on oncology.

Business Model:

Revenue: $68.2M

Employees: 201-500

Detailed Biocartis Information

Geographic Data

Biocartis headquarters map

Address: Generaal de Wittelaan 11B

City: Mechelen

State: antwerp

Zip: B-2800

Country: BE

Financial Info

Stage:

grant

Raised Last:

$1M

Raised Total:

$418M

Metrics

2,335,380Website Global Rank

7,969Website Monthly Traffic

Twitter Followers

Description

Biocartis is a Belgium-based diagnostics company that provides testing solutions for the treatment of cancer and infectious diseases with a focus on oncology.

Contact Phone:
+13215632600

Contact Email:

Biocartis went public on 4/24/2015 on the NYSE Euronext

Listed Exchange:
NYSE Euronext

IPO Date:
4/24/2015

IPO Valuation:
$490M

Ticker Symbol:
BCART

IPO Price:
$12.504390128273297/share

Amount Raised:
$109M

Live

Opened: -/share

EBITDA -
Total Cash -
Total Debt -
Total Revenue -
Total Profit (Gross) -
PE Ratio -
Announced Date Company Transaction Money Raised
6/2021 Geneprodx Series A 3.2M
6/2012 Immunexpress Venture Round 2M
6/2021 Geneprodx Series A 0
6/2012 Immunexpress Venture Round 0

Startup Industries

Startup Locations

Portfolio Current Status

Portfolio Employee Count

Announced Date Transaction Number of Investors Money Raised Lead Investors
11/2017 Post-IPO Equity $94.8M
6/2014 Grant $2.3M
10/2009 Series A 2 $14.9M Aescap Venture
Advent Venture Partners
Aescap Venture
Advent Venture Partners
9/2020 Grant 1 $1.4M Flanders Innovation and Entrepreneurship (VLAIO)
Flanders Innovation and Entrepreneurship (VLAIO)
Flanders Innovation and Entrepreneurship (VLAIO)
Flanders Innovation and Entrepreneurship (VLAIO)
11/2011 Series C 3 $95.8M Wellcome Trust
Johnson &a; Johnson Development Corporation
Debiopharm Group
Wellcome Trust
Johnson &a; Johnson Development Corporation
Debiopharm Group
5/2021 Grant $1.7M VLAIO
4/2010 Series B 5 $40M Aescap Venture
KBC
Johnson &a; Johnson Development Corporation
Debiopharm Group
Advent Venture Partners
Aescap Venture
KBC
Johnson &a; Johnson Development Corporation
Debiopharm Group
Advent Venture Partners
9/2014 Series F $0 Hitachi Chemical Diagnostics
Johnson &a; Johnson Development Corporation
PMV Tina Fund
Hitachi Chemical Diagnostics
Johnson &a; Johnson Development Corporation
PMV Tina Fund
2/2018 Post-IPO Debt $29.3M
1/2019 Private Placement $63.1M
11/2013 Series E $0 Koninklijke Philips
PMV Tina Fund
RMM
Philips Venture Capital Fund
Valiance Asset Management
Johnson &a; Johnson Development Corporation
Debiopharm Innovation Fund
Wellcome Trust
Koninklijke Philips
PMV Tina Fund
RMM
Philips Venture Capital Fund
Valiance Asset Management
Johnson &a; Johnson Development Corporation
Debiopharm Innovation Fund
Wellcome Trust
9/2018 Unattributed $138.4k
12/2012 Series D $0 PMV Tina Fund
New Rhein
Benaruca
Debiopharm Group
Johnson &a; Johnson Development Corporation
Korys
Luc Verelst
Paul Janssen
Philips Venture Capital Fund
RMM
Valiance Asset Management
PMV Tina Fund
New Rhein
Benaruca
Debiopharm Group
Johnson &a; Johnson Development Corporation
Korys
Luc Verelst
Paul Janssen
Philips Venture Capital Fund
RMM
Valiance Asset Management
9/2020 Grant $1.4M VLAIO
9/2020 Grant 1 $1.4M Flanders Innovation and Entrepreneurship (VLAIO)
Flanders Innovation and Entrepreneurship (VLAIO)
Flanders Innovation and Entrepreneurship (VLAIO)
Flanders Innovation and Entrepreneurship (VLAIO)
11/2017 Post-IPO Equity $94.8M
9/2014 Series F 3 $83.4M Hitachi Chemical Diagnostics
PMV Tina Fund
Johnson &a; Johnson Development Corporation
Hitachi Chemical Diagnostics
PMV Tina Fund
Johnson &a; Johnson Development Corporation
6/2014 Grant $2.3M
11/2013 Series E 8 $40.4M PMV Tina Fund
RMM
Philips Venture Capital Fund
Valiance Asset Management
Koninklijke Philips
Johnson &a; Johnson Development Corporation
PMV Tina Fund
RMM
Philips Venture Capital Fund
Valiance Asset Management
Koninklijke Philips
Johnson &a; Johnson Development Corporation
12/2012 Series D 11 $45M PMV Tina Fund
PMV Tina Fund
11/2011 Series C 3 $95.8M
4/2010 Series B 5 $40M Aescap Venture
Aescap Venture
10/2009 Series A 2 $14.9M Aescap Venture
Aescap Venture
Announced Date Name Price

Employee Departments

Employee States

Uniview Singapore VEID Logo
Uniview Singapore VEID
Revenue: 0 - 100000
Employees:
Industry: Software
Details
Konkuk University Medical Center Logo
Konkuk University Medical Center
Revenue: 0 - 100000
Employees: 51 - 500
Industry: Education
Details
Daemon Technologies Logo
Daemon Technologies
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Blockchain
Details
Ace International Trade Logo
Ace International Trade
Revenue: 0 - 100000
Employees: 11 - 50
Industry: Industrial
Details
An Hòa Communications Logo
An Hòa Communications
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Advertising
Details

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research